EP Patent

EP3490561A1 — Combinations for the treatment of cancer

Assigned to Ignyta Inc · Expires 2019-06-05 · 7y expired

What this patent protects

The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

USPTO Abstract

The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

Drugs covered by this patent

Patent Metadata

Patent number
EP3490561A1
Jurisdiction
EP
Classification
—
Expires
2019-06-05
Drug substance claim
No
Drug product claim
No
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.